"舍不得金弹子，打不到金凤凰，投入才有回报。"丹娜生物董事长周泽奇在接受中国证券报记者采访时 说。在研发创新上，周泽奇坚信企业需要坚持长期投入，"只有做好核心技术，才能长远发展，立于不 败之地"。2008年，周泽奇回国扎入生物医药行业，并于2014年创办侵袭性真菌病诊断企业丹娜生物， 成长为国内真菌病早期诊断的龙头企业之一。 历经11年，丹娜生物于2025年11月3日正式登陆北交所，成为北交所体外诊断产品（IVD）第一股。以 泛真菌检测产品为起点，丹娜生物不断丰富产品线，在行业内率先提出"5G+联合检测方案"，显著提高 了对多种病原微生物感染病症的精准诊断水平，为无数易感人群筑起生命防线。近日，由中国证券报联 合北京证券交易所开展的2025北交所万里行调研活动走进丹娜生物。 从泛真菌检测到"5G+联合检测方案" 构建核心技术的护城河 在丹娜生物的展示大厅里，一张张专利证书、一份份产品注册证书见证着企业的创新实力。截至2025年 10月，公司已取得91项境内外专利，其中发明专利48项；获得79项境内医疗器械产品注册及备案证书、 102项欧盟CE认证，其曲霉半乳甘露聚糖IgG抗体检测试剂、念珠菌甘露聚糖IgG抗体 ...

"舍不得金弹子，打不到金凤凰，投入才有回报。"丹娜生物董事长周泽奇在接受中国证券报记者采访时 说。在研发创新上，周泽奇坚信企业需要坚持长期投入，"只有做好核心技术，才能长远发展，立于不 败之地"。2008年，周泽奇回国扎入生物医药行业，并于2014年创办侵袭性真菌病诊断企业丹娜生物， 成长为国内真菌病早期诊断的龙头企业之一。 历经11年，丹娜生物于2025年11月3日正式登陆北交所，成为北交所体外诊断产品（IVD）第一股。以 泛真菌检测产品为起点，丹娜生物不断丰富产品线，在行业内率先提出"5G+联合检测方案"，显著提高 了对多种病原微生物感染病症的精准诊断水平，为无数易感人群筑起生命防线。近日，由中国证券报联 合北京证券交易所开展的2025北交所万里行调研活动走进丹娜生物。 ● 本报记者 郑萃颖 从泛真菌检测到"5G+联合检测方案" 2008年，彼时的周泽奇受邀回国，响应国家生物医药发展的号召，参与天津国际生物医药联合研究院的 建设。在调研中他发现，中国生物医药行业在病原微生物诊断赛道与国际先进水平存在差距，尤其是真 菌病诊断领域，长期处于被忽略的状态。"肺炎有真菌、细菌、支原体、衣原体等多种诱因，可临床常 ...

证券研究报告 2025 年 11 月 30 日 湘财证券研究所 行业研究 体外诊断行业周报 六部门发文增强消费品供需适配性，IVD 受益 --体外诊断行业周报 11.24-11.28 相关研究： 核心要点： 本周医药生物上涨 2.67%，体外诊断上涨 2.63% 根据 Wind 数据，本周申万一级行业医药生物上涨 2.67%，涨幅排名位列申 万 31 个一级行业第 17 位。沪深 300 指数上涨 1.64%，医药跑赢沪深 300 指数 1.03 个百分点。 申万医药生物二级子行业医疗服务 II 报收 6237.83 点，上涨 1.42%；中药 II 报收 6419.16 点，上涨 1.29%；化学制药Ⅱ报收 12983.45 点，上涨 4.19%； 生物制品Ⅱ报收 6303.79 点，上涨 2.06%；医药商业Ⅱ报收 5079.66 点，上 涨 2.77%；医疗器械 II 报收 6403.08 点，上涨 2.30%。三级行业中体外诊 断报收 8251.20 点，上涨 2.63%。 从医疗服务板块公司的表现来看，表现居前的公司有：浩欧博（+14.3%）、 硕世生物（+13.6%）、英诺特（+13.3%）、中源 ...

作为科创板首家IVD（体外诊断）上市企业，热景生物正沿着国家生物制造战略的指引，完成一场从体 外诊断到生物医药的自然进阶。 "我们始终聚焦'唯一性、第一性'。"林长青指向肝癌早筛区域介绍。科技创新是热景生物的核心基因。 2019年科创板上市时，公司的上转发光方法学就已斩获国家技术发明奖二等奖，成为当时体外诊断领域 罕见获此殊荣的方法学。 热景生物董事长林长青日前在接受上海证券报记者专访时表示，公司的转型并非跨界突围，而是基于生 物技术核心竞争力的延伸，在创新药赛道坚持长期主义，同时以全球化布局打开增长新空间，在生物医 药的"长坡厚雪"中稳步前行。 立足核心技术，顺应产业趋势 生物制造已被列为国家未来十年战略性新兴产业，而生物医药作为其技术壁垒最高的领域之一，成为产 业升级的关键战场。在林长青看来，热景生物从体外诊断向生物医药的拓展，本质上是生物技术应用的 自然延伸。 "体外诊断与抗体药的核心技术都是单克隆抗体，前者用于诊断检测，后者用于疾病治疗。生物技术的 范畴里，没有生硬地分层医疗器械体外诊断或者是生物医药。"林长青强调，其本质是"同一棵树上的不 同果实"。 这种技术同源的认知，让热景在战略布局上更加从容。 ...

Core Viewpoint - The leading medical information technology company, Chuangye Huikang, is set to change ownership as Hangzhou Genghao Investment Management Partnership has initiated a share transfer process, marking a significant shift in control amidst declining performance for both companies [1][8]. Group 1: Ownership Change - Hangzhou Genghao has paid approximately 158 million yuan as the first installment for the share transfer [1]. - The agreement involves Hangzhou Genghao acquiring 9,652,509 shares from the largest shareholder, Ge Hang, representing 6.23% of the total share capital, at a price of 5.18 yuan per share, totaling 500 million yuan [3][4]. - Following the transfer, Hangzhou Genghao's voting rights will increase from 0% to 12.64%, making it the largest shareholder of Chuangye Huikang [4]. Group 2: Financial Performance - Chuangye Huikang has experienced three consecutive years of declining performance, with a reported net loss of 173 million yuan in 2024, marking its first loss since going public [9]. - For the first three quarters of 2025, the company reported a revenue of 862 million yuan, a decrease of 26.26% year-on-year, and a net loss of 122 million yuan, a staggering decline of 331.69% [10]. - Hangzhou Genghao's parent company, Huajian Medical, also reported a decline in performance, with a revenue of 1.27 billion yuan in the first half of 2025, down 6.2%, and a net profit of 38.32 million yuan, down 70% [7][8]. Group 3: Strategic Intent - The acquisition aims to position Chuangye Huikang as a leader in the AI healthcare sector, with plans for board restructuring and potential capital increases to enhance control [5][8]. - Chuangye Huikang, founded in 1997, focuses on medical information services and has seen its market value drop significantly from over 20 billion yuan at its peak [8][10].

◎记者 夏子航 11月25日，阿里健康与体外诊断行业头部上市公司圣湘生物正式签署战略合作协议。双方将聚焦呼吸道 感染性疾病领域，围绕检测产品、技术服务与创新模式展开全面业务合作，共同推动专业级呼吸道检测 能力向家庭场景延伸，助力淘宝闪购"居家闪检"服务体验升级。 近年来，阿里、京东、美团等互联网平台纷纷布局居家检测这一新风口。 一家互联网平台居家检测业务相关负责人向上海证券报记者表示，借助居家检测、可穿戴设备和连续数 据流，医疗健康行业有望迎来新机遇。"短期内，我们将开放检测与服务能力，接入更多合作伙伴，共 同拓展市场，提升服务能力；长期来看，我们将构建'检测—诊疗—用药—管理'的大健康生态蓝图。" 阿里健康与圣湘生物达成战略合作 11月18日，阿里健康联合淘宝闪购在北京、上海、广州、杭州四地率先推出"居家闪检"服务，上线 了"呼吸道病毒细菌12联检"项目，一次性覆盖甲型流感病毒、乙型流感病毒、肺炎支原体、新型冠状病 毒、腺病毒等12种常见呼吸道病原体，满足流感高发季多样化的检测需求。 用户在淘宝App搜索"居家闪检"进入服务页面预约后，由经过专业培训的骑手上门送达采样包，并协助 完成咽拭子样本采集，随后样本 ...

Core Viewpoint - The company is actively integrating AI technologies, such as DeepSeek, into its clinical testing and auxiliary detection systems to enhance efficiency and accuracy in medical data research [1] Group 1: AI Integration - The company utilizes various AI models, including DeepSeek and Tongyi Qianwen, to improve detection efficiency and accuracy in different testing scenarios [1] - The company aims to deepen the application of AI technology in the in vitro diagnostic field, promoting product innovation to meet market demands for efficient and precise testing [1] Group 2: Market Response - The company expresses gratitude for investor support and emphasizes the importance of rational investment decisions regarding AI and medical-related business developments [1]

Core Insights - The biomanufacturing industry in China is entering a historic policy window, driven by the inclusion of biomanufacturing in the "14th Five-Year Plan" and the implementation of the "Regulations on the Management of Clinical Research and Clinical Translation Applications of Biomedical New Technologies" [1][10] - Leading in vitro diagnostic company, Sansure Biotech, is aligning its strategic development with national policies, focusing on high-quality innovation and technological self-reliance to transition from "following innovation" to "source innovation" [1][2] Policy Direction and Strategic Layout - The combination of the "14th Five-Year Plan" and the new regulations provides strong support for the biomanufacturing industry, emphasizing high-quality innovation and technological independence [2] - Sansure Biotech is integrating AI technology into its diagnostic platform, establishing a vertical integration capability from raw materials to large-scale production and intelligent terminals [2][3] Product Development and Market Positioning - The company is enhancing its diagnostic capabilities in respiratory and HPV fields, ensuring precision in diagnosis while promoting convenient and home-based testing solutions [3][4] - Sansure Biotech has achieved significant growth in its sequencing business, with a 150% year-on-year increase in the first three quarters, and has received over 130 new domestic and international certifications this year [4] Competitive Advantages and Global Strategy - Sansure Biotech aims to become a platform-based ecological enterprise, focusing on "products + services + digital empowerment" to enhance its competitive edge [5][7] - The company is expanding its global market presence by implementing a strategy of "deepening emerging markets and breaking into high-end markets," with a focus on localized production and regional R&D centers [7][9] Innovation Goals and Future Outlook - The company has set clear innovation goals for the "14th Five-Year Plan," aiming to transition into a platform-based ecological enterprise driven by product, service, and digital empowerment [8][10] - Sansure Biotech plans to leverage national strategies and market demands, utilizing AI technology and ecological construction to capture opportunities in the global biomanufacturing landscape [10]

据阿里健康消息，11月25日，阿里健康与国内体外诊断领军企业圣湘生物正式签署战略合作协议。双方 将聚焦呼吸道感染性疾病领域，围绕检测产品、技术服务与创新模式展开全面业务合作。 ...

Group 1 - Beijing Junzheng adjusted management expenses by 11.44 million yuan, increasing net profit by the same amount [1] - Ningbo Energy's subsidiary plans to publicly transfer 15% equity of Lingfeng Energy at a base price of 16.06 million yuan [1] - Dongjiang Environmental's subsidiary was fined 2.02 million yuan for tax evasion [1][2] Group 2 - AVIC's subsidiary Harbin Aircraft Industry Group plans to absorb and merge with Harbin Hafei Aviation, increasing registered capital to 3.038 billion yuan [3] - Dongfang Ocean's shareholder plans to reduce holdings by up to 3% of total shares [4] - Xinghui Entertainment's controlling shareholder plans to reduce holdings by up to 2.9% of total shares [6] Group 3 - Kaineng Health plans to acquire 100% equity of four subsidiaries for 204 million yuan [8] - Suoao Sensor's controlling shareholder changed to Zhongchuang Innovation [9] - Shanghai Port Bay reported that its commercial aerospace and perovskite solar business accounts for less than 1% of revenue [10] Group 4 - Zhonghuan Environmental's specific shareholder plans to reduce holdings by up to 2.37% of total shares [11] - Xinlaifu's asset management plan intends to reduce 874,300 shares [12] - Guangdian Measurement plans to invest 800 million yuan to build a testing base [13] Group 5 - Modern Investment plans to invest 1.04 billion yuan to establish a smart logistics company [14] - Gaole Co.'s major shareholder is planning a control change, leading to stock suspension [16] - Weiling Co.'s major shareholder is planning a control change, leading to stock suspension [18] Group 6 - Igor plans to issue H-shares and apply for listing on the Hong Kong Stock Exchange [20] - Huanrui Century's shareholder sold 7.26 million shares due to judicial enforcement [21] - Jinhua Co.'s controlling shareholder plans to acquire 5.77% of company shares at 9.15 yuan per share [22] Group 7 - Wireless Media's four shareholders plan to reduce holdings by up to 4.7% of total shares [24] - CATL's shareholder completed the transfer of 10% of shares for approximately 17.16 billion yuan [26] - *ST Lian Stone entered the restructuring phase, with potential downward adjustment of stock price [28]